FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940200542> ?p ?o ?g. }

• W2940200542 endingPage "978" @default.
• W2940200542 startingPage "968" @default.
• W2940200542 abstract "Summary Objective Increased activity of T‐type Ca 2+ channels is linked to idiopathic generalized epilepsies, thus blocking these channels may be a new treatment option. ACT ‐709478 is an orally available triple T‐type Ca 2+ channel blocker. The aim of this first‐in‐man study was to investigate the pharmacokinetics, pharmacodynamics, tolerability, and safety of single doses of ACT ‐709478 in healthy subjects. Methods This double‐blind, placebo‐controlled, randomized study included 65 healthy male subjects. Ascending single oral doses of 1‐400 mg ACT ‐709478 or placebo were administered to sequential groups of eight subjects (6 on active, 2 on placebo). Effect of food was tested in a crossover part at 60 mg. Blood and saliva sampling for pharmacokinetic evaluations and safety assessments was performed regularly. Effects on the central nervous system were assessed with a battery of pharmacodynamic tests. Results The maximum plasma concentration ( C max ) was reached within 3 to 4 hours (≤60 mg) and within 20 to 28 hours (>60 mg), and across all dose levels the terminal half‐life (95% confidence interval) ranged from 36 (29‐45) to 43 (22‐86) hours. Multiple peaks were observed and C max and area under the plasma concentration‐time curve (AUC) 0‐∞ increased in a less than dose‐proportional manner. A 1.6‐fold increase in C max and no change in AUC 0‐∞ was observed in fed compared to fasted conditions. A significant correlation ( P < 0.0001) between plasma and saliva concentrations was established using linear regression. All adverse events were transient and of mild or moderate intensity. No treatment‐related effects on vital signs, clinical laboratory, telemetry, or electrocardiography were detected. The results of pharmacodynamic tests did not show relevant mean changes compared to baseline or placebo. Significance ACT ‐709478 exhibits good tolerability and safety after single‐dose administration and its pharmacokinetic and pharmacodynamic properties warrant further investigations." @default.
• W2940200542 created "2019-04-25" @default.
• W2940200542 creator A5001293261 @default.
• W2940200542 creator A5051522593 @default.
• W2940200542 creator A5058093690 @default.
• W2940200542 creator A5072257915 @default.
• W2940200542 date "2019-04-20" @default.
• W2940200542 modified "2023-10-16" @default.
• W2940200542 title "First‐in‐man study of <scp>ACT</scp> ‐709478, a novel selective triple T‐type calcium channel blocker" @default.
• W2940200542 cites W1559837393 @default.
• W2940200542 cites W1568390163 @default.
• W2940200542 cites W1577969467 @default.
• W2940200542 cites W1845250825 @default.
• W2940200542 cites W1974506402 @default.
• W2940200542 cites W1991289683 @default.
• W2940200542 cites W1996190454 @default.
• W2940200542 cites W2000092715 @default.
• W2940200542 cites W2001316795 @default.
• W2940200542 cites W2008977146 @default.
• W2940200542 cites W2012417774 @default.
• W2940200542 cites W2025213140 @default.
• W2940200542 cites W2033679125 @default.
• W2940200542 cites W2068060863 @default.
• W2940200542 cites W2081017554 @default.
• W2940200542 cites W2082771245 @default.
• W2940200542 cites W2083767335 @default.
• W2940200542 cites W2088788142 @default.
• W2940200542 cites W2092129340 @default.
• W2940200542 cites W2096266931 @default.
• W2940200542 cites W2096701787 @default.
• W2940200542 cites W2113307128 @default.
• W2940200542 cites W2117496744 @default.
• W2940200542 cites W2131375845 @default.
• W2940200542 cites W2131404417 @default.
• W2940200542 cites W2137305727 @default.
• W2940200542 cites W2149918533 @default.
• W2940200542 cites W2171830917 @default.
• W2940200542 cites W2618654088 @default.
• W2940200542 cites W2767602037 @default.
• W2940200542 cites W2910008477 @default.
• W2940200542 cites W2912991414 @default.
• W2940200542 cites W3266514 @default.
• W2940200542 cites W4235960403 @default.
• W2940200542 cites W2033799732 @default.
• W2940200542 doi "https://doi.org/10.1111/epi.14732" @default.
• W2940200542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31004346" @default.
• W2940200542 hasPublicationYear "2019" @default.
• W2940200542 type Work @default.
• W2940200542 sameAs 2940200542 @default.
• W2940200542 citedByCount "7" @default.
• W2940200542 countsByYear W29402005422020 @default.
• W2940200542 countsByYear W29402005422021 @default.
• W2940200542 countsByYear W29402005422022 @default.
• W2940200542 countsByYear W29402005422023 @default.
• W2940200542 crossrefType "journal-article" @default.
• W2940200542 hasAuthorship W2940200542A5001293261 @default.
• W2940200542 hasAuthorship W2940200542A5051522593 @default.
• W2940200542 hasAuthorship W2940200542A5058093690 @default.
• W2940200542 hasAuthorship W2940200542A5072257915 @default.
• W2940200542 hasConcept C111113717 @default.
• W2940200542 hasConcept C112705442 @default.
• W2940200542 hasConcept C126322002 @default.
• W2940200542 hasConcept C142724271 @default.
• W2940200542 hasConcept C178790620 @default.
• W2940200542 hasConcept C185592680 @default.
• W2940200542 hasConcept C197934379 @default.
• W2940200542 hasConcept C204787440 @default.
• W2940200542 hasConcept C27081682 @default.
• W2940200542 hasConcept C2776414672 @default.
• W2940200542 hasConcept C2778375690 @default.
• W2940200542 hasConcept C2988731192 @default.
• W2940200542 hasConcept C42219234 @default.
• W2940200542 hasConcept C44249647 @default.
• W2940200542 hasConcept C504460877 @default.
• W2940200542 hasConcept C50952357 @default.
• W2940200542 hasConcept C537181965 @default.
• W2940200542 hasConcept C71924100 @default.
• W2940200542 hasConcept C76318530 @default.
• W2940200542 hasConcept C87813604 @default.
• W2940200542 hasConcept C98274493 @default.
• W2940200542 hasConceptScore W2940200542C111113717 @default.
• W2940200542 hasConceptScore W2940200542C112705442 @default.
• W2940200542 hasConceptScore W2940200542C126322002 @default.
• W2940200542 hasConceptScore W2940200542C142724271 @default.
• W2940200542 hasConceptScore W2940200542C178790620 @default.
• W2940200542 hasConceptScore W2940200542C185592680 @default.
• W2940200542 hasConceptScore W2940200542C197934379 @default.
• W2940200542 hasConceptScore W2940200542C204787440 @default.
• W2940200542 hasConceptScore W2940200542C27081682 @default.
• W2940200542 hasConceptScore W2940200542C2776414672 @default.
• W2940200542 hasConceptScore W2940200542C2778375690 @default.
• W2940200542 hasConceptScore W2940200542C2988731192 @default.
• W2940200542 hasConceptScore W2940200542C42219234 @default.
• W2940200542 hasConceptScore W2940200542C44249647 @default.
• W2940200542 hasConceptScore W2940200542C504460877 @default.
• W2940200542 hasConceptScore W2940200542C50952357 @default.
• W2940200542 hasConceptScore W2940200542C537181965 @default.
• W2940200542 hasConceptScore W2940200542C71924100 @default.

• next